Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh-Reference-Cited by-同舟云学术

Response to concerns over Cantillon et al. dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings (SCHRES-D-17-00455) by Ahmed S Aboraya, MD, DrPh

Published:2018-05 Issue: Volume:195 Page:581-582
ISSN:0920-9964
Container-title:Schizophrenia Research
language:en
Short-container-title:Schizophrenia Research

Author:

Cantillon Marc,Bhat Laxminarayan

Funder

Reviva Pharmaceutical

Publisher

Elsevier BV

Subject

Biological Psychiatry,Psychiatry and Mental health

Reference10 articles.

1. Concerns over Cantillon et al. Dopamine serotonin stabilizer RP5063 clinical trial's design, analyses and findings;Aboraya;Schizophr. Res.,2018

2. A novel approach to measuring response and remission in schizophrenia in clinical trials;Aboraya;Schizophr. Res.,2017

3. Remission in schizophrenia: proposed criteria and rationale for consensus;Andreasen;Am. J. Psychiatry,2005

4. Dopamine serotonin stabilizer RP5063: A randomized, double-blind, placebo-controlled multicenter trial of safety and efficacy in exacerbation of schizophrenia or schizoaffective disorder;Cantillon;Schizophr. Res.,2011

5. Positive and Negative Syndromes in Schizophrenia;Kay,1991

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. New and emerging treatments for schizophrenia: a narrative review of their pharmacology, efficacy and side effect profile relative to established antipsychotics;Neuroscience & Biobehavioral Reviews;2022-01

Serotonin Type 6 and 7 Receptors as a Novel Therapeutic Target for the Treatment of Schizophrenia

;Neuropsychiatric Disease and Treatment;2020-10